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INTRODUCTION
Asthma is the most common chronic airway inflammatory dis-
ease in childhood. Approximately 40% of all young children 
experience at least one episode of asthmatic symptoms such 
as coughing, wheezing, and dyspnea.1,2 Asthma is character-
ized by bronchial hyper-responsiveness and chronic airway 
inflammation. Various cells, cytokines, and mediators partici-
pate in the process.3 In addition to local inflammation, system-
ic inflammation is also present in asthma. This is indicated by 
the increase in plasma fibrinogen and serum amyloid A levels 
in asthmatic patients.4,5 However, its pathogenesis remains 
unclear.
C-reactive protein (CRP), named after its capacity to precipi-
tate the somatic C-polysaccharide of Streptococcus pneumoni-
ae, was the first acute-phase reactant to be described. It is 
widely used as a marker for inflammation and tissue injury.6,7 
Assays for CRP, although simple and cost-effective, lacked the 
sensitivity using conventional methods. Standard assays of 
CRP, with its lower detection limit of 3–8 mg/L, could not de-
tect low-grade inflammation.8,9 However, recent advancements 
have made high-sensitivity assays for CRP available in clinical 
laboratories. High-sensitivity assays for CRP, reported to have 
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100-fold higher sensitivity than standard assays, can detect CRP 
at extremely low concentrations with its lower detection limit 
of 0.1–0.2 mg/L.9,10 CRP measured using high-sensitivity assays 
is referred to as high-sensitivity CRP (hs-CRP). Application of 
hs-CRP revealed the presence of low-grade inflammation in 
several disorders, such as cardiovascular disorders and diabe-
tes mellitus.11
With its ability to detect even low-grade inflammation, it is 
now thought that hs-CRP can reflect systemic inflammation 
in asthma.2,4,5 It has been reported that asthmatic patients have 
higher serum hs-CRP levels than healthy controls.2,4,5,9,10,12-14 
Negative relationships between serum hs-CRP levels and spi-
rometry indices were reported, reflecting positive associations 
between increased serum hs-CRP levels and respiratory im-
pairment.9,15-17 Positive relationships between serum hs-CRP 
level and asthma severity have also been reported.2,13,14,18,19 A 
study with pediatric subjects showed that serum hs-CRP lev-
els were higher in asthmatic patients than in healthy controls, 
and that there were positive associations between serum hs-
CRP levels and asthma severity.2,19
In this context, we designed a study to check if there are any 
significant relationships between symptomatic severities of 
asthma, pulmonary function test (PFT)–spirometry and im-
pulse oscillometry (IOS)–parameters, and hs-CRP in asthmatic 
children.
MATERIALS AND METHODS
Subjects
This study included 276 asthmatic children who visited the 
Pulmonology and Allergy Department of Severance Children’s 
Hospital from January 2012 to April 2014. Blood sampling, PFT, 
and histories to determine symptomatic severities were con-
ducted on the day of the clinic visit. Exclusion criteria included 
fever, acute respiratory infections, and signs of other acute in-
fections seven days prior to blood sampling. Patients with other 
comorbidities that can influence the levels of hs-CRP, such as 
diabetes mellitus, cancer, recent history of surgery, and chronic 
inflammatory conditions like systemic lupus erythematosus, 
rheumatic arthritis, and inflammatory bowel disease were also 
excluded.
Patients were classified as asthmatic patients if they showed 
any typical asthma symptoms–such as wheezing, cough, or 
dyspnea–together with reversibility in airflow obstruction or 
bronchial hyper-responsiveness. Reversibility in airflow ob-
struction was defined as an increase in the forced expiratory 
volume in 1 second (ΔFEV1) ≥12% from baseline after inhala-
tion of a short-acting beta-2 agonist. Bronchial hyper-respon-
siveness was defined as a positive result in bronchoprovoca-
tion by the methacholine challenge test (MCT). This meant that 
provocation concentration resulted in a 20% fall in FEV1 (PC20) 
≤16 mg/mL.20
All patients were then divided into two groups based on 
whether they had positive hs-CRP values or negative hs-CRP 
values. The reference ranges of CRP and hs-CRP are <10 mg/L 
and <3 mg/L, respectively.21,22 Therefore, the cut-off value of 
hs-CRP was set to 3.0 mg/L, making hs-CRP ≥3.0 mg/L positive, 
and hs-CRP <3.0 mg/L negative.
Patients were also divided into two groups according to their 
neutrophil counts: the high neutrophil group with neutrophil 
counts ≥median of neutrophil counts of all patients (3665/μL) 
and the low neutrophil group with neutrophil counts <median. 
Patients were likewise divided according to eosinophil counts 
into a high eosinophil group with eosinophil counts ≥median 
of eosinophil counts of all patients (350/μL) and a low eosino-
phil group with eosinophil counts <median. Within each group, 
patients were further divided into positive and negative hs-CRP 
subgroups, and their spirometry and IOS parameters were 
compared separately.
This study was approved by the Institutional Review Board 
of Severance Hospital (Seoul, Korea, IRB No. 4-2004-0036).
Laboratory tests and allergy screening tests
From the sampled blood, a complete blood count (CBC), in-
cluding white blood cell (WBC), neutrophil, and eosinophil 
counts, as well as total and specific immunoglobulin E (IgE) 
and hs-CRP levels were measured. The CBC was measured 
using the ADVIA 2120i hematology system with autoslide (Sie-
mens Healthcare Diagnostics Inc., Deerfield, IL, USA), hs-CRP 
using the Hitachi 7600 P module (Hitachi High-Technologies 
Corporation, Tokyo, Japan), and total and specific IgE using 
the Pharmacia CAP assay (Uppsala, Sweden).
Skin prick tests were done for 12 common aeroallergens, 
which included two types of dust mites, cat and dog epithelia, 
as well as mold and pollen allergens such as Alternaria, Asper-
gillus, birch, oak, mugwort, Japanese hop, ragweed, and Ber-
muda grass. Negative control (using saline solution) and posi-
tive control (using 0.5% histamine hydrochloric acid solution) 
were conducted simultaneously. A positive reaction was de-
fined as a wheal of diameter >3 mm after 15 minutes.
Atopy was defined as specific IgE >0.7 kU/L to more than 1 
allergen, total IgE >150 IU/mL, or one or more positive skin re-
actions to 12 common aeroallergens.
Spirometry and impulse oscillometry
The Jaeger MasterScreen PFT system (Jaeger Co., Wurzberg, 
Germany) was used for spirometry and the MCT. Flow-volume 
curves were acquired, according to the American Thoracic So-
ciety guidelines, before and after inhalation of a short-acting 
beta 2 agonist. For the MCT, increasing concentrations of 
methacholine (0.075, 0.15, 0.31, 0.62, 1.25, 2.5, 5, 10, 25, and 
50), nebulized by the dosimeter (MB3; Mefar; Bresica, Italy), 
were inhaled by each patient until FEV1 was reduced by 20% 
from a post-nebulized saline solution value. Provocation con-
centration causing a 20% fall in FEV1 (PC20) was calculated by 
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linear interpolation of the log dose-response curve.
The Jaeger MasterScreen IOS system (Jaeger Co., Wurzberg, 
Germany) was used for IOS. IOS was performed prior to spi-
rometry, both before and after bronchodilator inhalation, to 
avoid any possible influence by forced breathing during spi-
rometry. Calibration of the system was performed through a 
single volume of air (3 L) at different flow rates using a refer-
ence device (0.2 kPa/L/s). The machine was also calibrated to 
the air temperature and pressure of the saturated gas. The im-
pulse generator produced pressure pulses at intervals of 0.2 
seconds. From the measurement over 60 seconds, the mean 
resistance (R) values were calculated at frequencies of 5 Hz (R5) 
and 10 Hz (R10), and the reactance (X) values were calculated 
at 5 Hz (X5). The reactance area (AX), which is an integrated re-
sponse index for reactance developed by Goldman,23 was also 
computed. It demonstrates the integral of the negative values 
of reactance from 5 Hz to the resonant frequency. The differ-
ence between R5 and R20 (R5–R20) was also calculated as the 
parameter of small airway obstruction, since R5 demonstrates 
obstruction in total airways, while R20 demonstrates obstruc-
tion in only the large airways. X5 and AX also demonstrate ob-
struction of peripheral airways.24
During IOS, patients sat upright with their heads placed 
against the back of the chair. While wearing nose clips, they 
were instructed to breathe quietly through a mouthpiece. In 
order to minimize shunt compliance of the cheeks and to ob-
serve for any artifacts produced by coughing, breath holding, 
swallowing, or vocalization, an investigator supported the pa-
tients’ cheeks and chins from behind. Three correct measure-
ments without any artifacts were averaged using an acceptable 
coherence value of ≥0.8 at 10 Hz.24
Statistical analysis
The values that follow parametric distributions are expressed 
as mean±standard deviation, while the values that follow non-
parametric distributions are expressed as median with inter-
quartile ranges. Comparisons of two groups were performed 
using t tests or Fisher’s exact tests if the data were parametric 
and continuous, or using Kruskal-Wallis test and Mann-Whit-
ney test if the data were non-parametric and continuous. If 
the data were categorical variables, the chi-square test was 
used. Correlations between data were analyzed using Spear-
man’s rank correlation test.
A p value of <0.05 was considered significant. The Statistical 
Package for the Social Sciences (version 18.0, SPSS Inc., Chica-
go, IL, USA) was used for all analyses.
RESULTS
Clinical characteristics, asthma severity, and hs-CRP
The median age of the 276 patients was 7.5 (5.9/10.1) years, 
with 171 (62%) patients being boys. Among them, 39 patients 
had positive hs-CRP values, while 237 patients had negative 
hs-CRP values. Patients were divided into two groups by hs-
CRP levels; however, there were no significant differences in 
age, gender, atopy (defined based on their specific IgE, total 
IgE, and results of the skin prick tests), WBC count, neutrophil 
count, eosinophil count, total IgE level, or body mass index 
between the groups (Table 1). The patients were categorized 
by asthma severity into three groups according to the National 
Heart, Lung, and Blood Institute (NHLBI) guidelines: 146 pa-
tients were intermittent, 74 were mild persistent, and 56 were 
moderate to severe persistent.20 Median hs-CRP values were 
as follows: intermittent group, 0.5 (0.4/1.2), mild persistent 
group, 0.6 (0.4/1.2), and the moderate to severe persistent 
group, 0.6 (0.4/1.7). There was no significant difference in hs-
CRP values among the three asthma severity groups (p=0.706). 
Table 1. Comparison of Clinical Characteristics between Patients in Positive and Negative hs-CRP Groups (n=276)
Positive hs-CRP (n=39) Negative hs-CRP (n=237)
Age, yrs 6.5 (5.4/4.9) 7.6 (6.1/10.4)
Gender, male/female 25/14 146/91
Atopy 31 (79.5%) 172 (72.6%)
WBC, /μL 8000 (6380/11150) 7970 (6820/9555)
Neutrophil count, /μL 4210 (2810/6450) 3660 (2850/4650)
Eosinophil count, /μL 230 (160/470) 380 (180/560)
Total IgE, kU/L 297.0 (121.0/577.0) 194.5 (71.7/512.3)
BMI, kg/m2 16.8 (15.1/20.2) 16.7 (15.4/19.0)
hs-CRP, mg/L 6.7 (3.6/10.7) 0.5 (0.4/0.8)*
Severity according to NHLBI guidelines
Intermittent (n=146) 20 (51.3%) 126 (53.2%)
Mild persistent (n=74) 10 (25.6%) 64 (27.0%)
Moderate to severe persistent (n=56) 9 (23.1%) 47 (19.8%)
hs-CRP, high-sensitivity C-reactive protein; WBC, white blood cell; BMI, body mass index; NHLBI, national heart, lung, and blood institute.
Data are given as median (interquartile range) or number (%).
*p<0.05 vs. positive hs-CRP.
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There was also no significant difference in asthma severity be-
tween the positive hs-CRP group and the negative hs-CRP gr-
oup (Table 1).
Spirometry parameters and hs-CRP
We compared the forced vital capacity (FVC), % predicted 
FEV1, FEV1/FVC ratio in percentage, and FEF25–75, with hs-CRP. 
Out of these, FEV1 and FEF25–75 showed significant differences 
between positive and negative hs-CRP groups (Fig. 1). Among 
spirometry, only FEF25–75 had a significant negative correlation 
with hs-CRP (Table 2).
IOS parameters and hs-CRP
Among the IOS parameters, AX, R5–R20, R5, R10, and X5 were 
compared between the positive and negative hs-CRP groups. 
Out of these, AX, R5–R20, R5, and X5 showed significant dif-
ferences between the positive and negative hs-CRP groups (Fig. 
2). Among IOS parameters, only R5 and X5 showed significant 
positive correlation with hs-CRP values (Table 2).
Subgroup analysis according to blood neutrophil/
eosinophil levels
The high and low neutrophil groups were each comprised of 
138 patients. In the high neutrophil group, there were signifi-
cant differences in the FVC1, FEV1, FEF25–75, and X5 between the 
positive and negative hs-CRP subgroups. There were also sig-
nificant correlations between hs-CRP and FEF25–75, AX, R5, 
and X5, individually. Meanwhile, in the low neutrophil group, 
there was no significant association between the PFT param-
eters and hs-CRP (Table 3).
Similarly, all 276 patients were divided into high eosinophil 
(n=140) and low eosinophil (n=136) groups. In the high eosin-
ophil group, there was no significant association between the 
PFT parameters and hs-CRP. Meanwhile, in the low eosinophil 
group, there were significant differences in the FEV1, FEF25–75, 
AX, R5–R20, R5, and X5 between the positive and negative hs-
CRP subgroups, and hs-CRP had significant correlations with 
the FEV1, FEF25–75, R5–R20, R5, and X5 (Table 4).
DISCUSSION
This study is of significance because it is, to our best knowl-
edge, the first study that compared hs-CRP with IOS parame-
ters in asthmatic patients. In the present study, we found there 
were significant differences in the FEV1, FEF25–75, AX, R5–R20, 
R5, and X5 between the hs-CRP positive and negative groups. 
Hs-CRP also showed a significant negative correlation with 
Fig. 1. Comparisons of forced expiratory volume in 1 second, % predicted 
(FEV1) and maximum midexpiratory flow, % predicted (FEF25–75) between 
high-sensitivity C-reactive protein (hs-CRP) positive and negative groups. 
FEV1 (p=0.046) and FEF25–75 (p=0.010) were significantly lower in the hs-CRP 
positive group than in the negative group.
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Table 2. Correlations of hs-CRP and PFT Parameters 
Total (n=276) r p value
Spirometry parameters
FVC, % predicted 101.23±14.78 -0.034 0.574
FEV1, % predited 102.18±17.02 -0.094 0.118
FEV1/FVC (%) 87.17 (81.34/92.42) -0.087 0.149
FEF25–75, % predicted 84.31±26.13 -0.178 0.003
IOS parameters
AX, kPa/L 3.16 (2.00/4.20) 0.083 0.180
R5–R20, kPa/(L/s) 0.62 (0.51/0.79) 0.105 0.088
R5, % predicted 104.50 (86.40/126.00) 0.163 0.008
R10, % predicted 82.70 (73.30/95.90) 0.078 0.204
X5, % predicted 139.30 (111.60/175.90) 0.164 0.007
hs-CRP, high-sensitivity C-reactive protein; PFT, pulmonary function test; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25–75, maximum 
midexpiratory flow; IOS, impulse oscillometry; AX, reactance area; R5–R20, difference between resistance at 5 Hz and 20 Hz; R5, resistance at 5 Hz; R10, resis-
tance at 10 Hz; X5, reactance at 5 Hz.
Data are given as mean±standard deviation, median (interquartile range), or number. r, Spearman’s correlation coefficient.
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FEF25–75, and significant positive correlations with R5 and X5. 
The associations between hs-CRP and the PFT indices were 
stronger in patients with higher blood neutrophil counts than 
in patients with lower counts. However, hs-CRP showed no sig-
nificant relationship with symptomatic asthma severities.
CRP is an inflammatory marker synthesized mainly by he-
patocytes and Browicz-Kupffer cells, but also by monocytes 
and lymphocytes. Its main roles are recognition and elimina-
tion of bacteria and damaged cells through complement and 
activation of phagocytic cells.13,25 CRP has been widely used as 
an inflammatory marker because of its simple and cost-effec-
tive measurement methods; however, routine assays lacked the 
sensitivity to detect the presence of low concentrations of se-
rum CRP in chronic low inflammatory diseases. With the de-
velopment of high-sensitivity assays of CRP, the detection of 
subtle elevations of serum hs-CRP in conditions associated 
with chronic low-grade inflammation became possible. In-
deed, hs-CRP has been demonstrated to be a strong indepen-
dent predictor of future myocardial infarction, stroke, and pe-
ripheral arterial diseases in healthy people, as well as recurrent 
events in patients with coronary diseases.7,12,26 
Chronic airway inflammation is characteristic to asthma, but 
it has been proven that systemic inflammation is also pres-
ent.2,4,5 Systemic inflammation in asthma is supported by the 
Fig. 2. Comparisons of impulse oscillometry (IOS) parameters between high-sensitivity (hs-CRP) positive and negative groups. (A) Reactance area (AX) 
was significantly higher in the hs-CRP positive group than in the negative group (p=0.046). (B) Difference between resistance at 5 Hz and 20 Hz (R5–R20) 
was significantly higher in the hs-CRP positive group than in the negative group (p=0.027). (C) Resistance at 5 Hz, % predicted (R5) was significantly higher 
in the hs-CRP positive group than in the negative group (p=0.027). (D) Reactance at 5 Hz, % predicted (X5) was significantly higher in the hs-CRP positive 
group than in the negative group (p=0.041).
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increase in circulating pro-inflammatory cytokines, such as 
interleukin (IL)-6 and tumor necrosis factor (TNF)-α, a conse-
quent increase in acute-phase reactants such as CRP, and the 
presence of immune cells, such as neutrophils and natural kill-
er cells in asthmatic patients.27 Accordingly, several studies re-
port associations between hs-CRP, a sensitive marker of sys-
temic inflammation, and asthma. Serum hs-CRP levels in as-
thmatic patients were reportedly higher than in healthy con-
trols.5,9,10 This was the same in pediatric populations.2 Associ-
ations, such as a significant negative correlation between hs-
CRP and FEV115,17 or FEV1/FVC9,16 in asthmatic patients, between 
hs-CRP and spirometry indices have also been reported. How-
ever, the pathogenesis of systemic inflammation in asthmatic 
patients remains unclear. It may be because of an overspill ef-
fect of local airway inflammation, tissue hypoxia, subclinical re-
spiratory tract inflammation, or other environmental factors.28-31
In the present study, we found that FEV1 and FEF25–75 among 
spirometry parameters were significantly lower in the hs-CRP 
positive group than in the hs-CRP negative group, and that only 
FEF25–75 had a statistically significant negative correlation with 
hs-CRP. FEF25–75 reflects small airway patency and is reduced in 
asthmatic patients with a history of wheezing.32,33 Hs-CRP, th-
erefore, may have a greater association with small airway ob-
struction or inflammation.
IOS is a noninvasive technique to measure pulmonary im-
pedance, which comprises pulmonary resistance and reac-
tance.34 Since it is measured during normal tidal breathing, it 
is now popular for its applicability to younger children who are 
unable to conduct forced breathing, which is required to mea-
sure spirometry parameters. It is also highlighted as a marker 
for small airway obstruction. In the present study, AX, R5–R20, 
R5, and X5 were significantly higher in the hs-CRP positive 
group than in the hs-CRP negative group, and R5 and X5 sh-
owed statistically significant positive correlations with hs-CRP. 
A decrease in FEF25–75 and an increase in R5 and X5 are all char-
acteristics of small airway obstruction.24 Accordingly, serum 
Table 3. Comparison of Spirometry and IOS Parameters between Positive and Negative hs-CRP Groups, and Correlation between Spirometry and IOS 
Parameters and hs-CRP, within Separate High and Low Neutrophil Groups (n=276)
High neutrophil group (n=138) Low neutrophil group (n=138)
Positive hs-CRP
(n=21)
Negative hs-CRP
(n=117)
Correlation 
with hs-CRP
Positive hs-CRP
(n=18)
Negative hs-CRP 
(n=120)
Correlation 
with hs-CRP
FVC, % predicted 97 (81/107) 102 (93/110)* r=-0.105 101 (81/117) 101 (92/110) r=0.868
FEV1, % predicted 93 (78/109) 105 (94/114)* r=-0.153 101 (82/117) 103 (91/110) r=-0.052
FEV1/FVC, % 86 (76/92) 87 (82/92) r=-0.091 89 (80/94) 87 (81/93) r=-0.082
FEF25–75, % predicted 63 (44/95) 86 (70/105)* r=-0.197† 73 (60/110) 83 (64/101) r=0.063
AX, kPa/L 3.56 (2.56/4.83) 3.18 (2.00/4.19) r=0.178† 3.44 (2.19/4.65) 3.05 (1.99/3.91) r=-0.036
R5–R20, kPa/(L/s) 0.72 (0.55/0.85) 0.64 (0.51/0.79) r=0.138 0.74 (0.52/0.92) 0.60 (0.50/0.74) r=0.036
R5, % predicted 116 (103/136) 105 (84/131) r=0.231† 109 (90/137) 100 (86/119) r=0.048
X5, % predicted 176 (126/220) 142 (107/171)* r=0.282† 141 (120/171) 134 (109/173) r=0.025
IOS, impulse oscillometry; hs-CRP, high-sensitivity C-reactive protein; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25–75, maximum 
midexpiratory flow; AX, reactance area; R5–R20, difference between resistance at 5 Hz and 20 Hz; R5, resistance at 5 Hz; X5, reactance at 5 Hz.
Data are expressed as median (interquartile range). r, Spearman’s correlation coefficient.
*p<0.05 vs. positive hs-CRP, †p<0.05 in correlation with hs-CRP by Spearman’s rank correlation test.
Table 4. Comparison of Spirometry and IOS Parameters between Positive and Negative hs-CRP Groups, and Correlation between Spirometry and IOS 
Parameters and hs-CRP, within Separate High and Low Eosinophil Groups (n=276)
High eosinophil group (n=140) Low eosinophil group (n=136)
Positive hs-CRP
 (n=21)
Negative hs-CRP 
(n=117)
Correlation 
with hs-CRP
Positive hs-CRP
(n=18)
Negative hs-CRP 
(n=120)
Correlation 
with hs-CRP
FVC, % predicted 96 (78/111) 101 (94/109) r=-0.044 99 (83/116) 101 (92/112) r=-0.031
FEV1, % predicted 100 (76/112) 104 (92/111) r=-0.002 93 (79/113) 104 (95/114)* r=-0.181†
FEV1/FVC, % 89 (78/94) 86 (82/92) r=-0.022 87 (77/92) 88 (82/93) r=-0.160
FEF25–75, % predicted 74 (60/101) 81 (65/99) r=-0.600 70 (45/89) 91 (68/105)* r=-0.301†
AX, kPa/L 3.98 (2.46/4.79) 3.24 (2.12/4.26) r=0.028 3.51 (2.48/4.81) 2.89 (1.60/3.77)* r=0.154
R5–R20, kPa/(L/s) 0.70 (0.54/0.94) 0.66 (0.54/0.79) r=0.037 0.74 (0.55/0.88) 0.60 (0.46/0.68)* r=0.199†
R5, % predicted 108 (86/133) 103 (86/126) r=0.092 110 (102/142) 102 (84/118)* r=0.236†
X5, % predicted 135 (117/168) 133 (107/178) r=0.097 169 (123/210) 140 (114/166)* r=0.240†
IOS, impulse oscillometry; hs-CRP, high-sensitivity C-reactive protein; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25–75, maximum 
midexpiratory flow; AX, reactance area; R5–R20, difference between resistance at 5 Hz and 20 Hz; R5, resistance at 5 Hz; X5, reactance at 5 Hz.
Data are expressed as median (interquartile range). r, Spearman’s correlation coefficient.
*p<0.05 vs. positive hs-CRP, †p<0.05 in correlation with hs-CRP by Spearman’s rank correlation test.
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hs-CRP can reflect small airway inflammation.
CRP is a systemic marker for neutrophilic inflammation. In 
this context, Wood, et al.35 reported that hs-CRP was higher in 
patients with neutrophilic asthma. Some studies showed that 
hs-CRP had no association with markers of eosinophilic in-
flammation, history of atopy, or allergic sensitization,9,31,35,36 
while other studies reported that hs-CRP was increased in 
non-atopic asthmatic patients but not in atopic asthmatic pa-
tients.12,18,37 In the present study, when the subjects were sub-
divided according to their neutrophil and eosinophil levels, 
only patients in the high neutrophil and low eosinophil groups 
showed any statistically significant associations between se-
rum hs-CRP and PFT indices. This result shows that hs-CRP 
can reflect small airway obstruction in asthma with neutrophil 
dominant inflammation.
As mentioned above, the reason for the presence of systemic 
inflammation, especially neutrophilic inflammation, in asthma 
is still unknown. Hypotheses that cytokines from airway ‘spill 
over’ to systemic circulation have been proposed in chronic 
obstructive pulmonary disease, but not for asthma.38 However, 
Wood, et al.35 demonstrated that receptors α for IL-8 (IL8RA), 
which are highly selective for neutrophil chemotaxis, were el-
evated in neutrophilic asthma. Meanwhile, Fu, et al.39 showed 
that systemic inflammation in asthma was associated with a 
body of upregulated genes that were involved in IL-1, TNF-α/
nuclear factor-κB, and Kit receptor pathways, which were asso-
ciated with innate immune response, defense and inflamma-
tory responses, and particularly neutrophilic inflammation.
Navratil, et al.19 reported that serum hs-CRP was higher in 
uncontrolled asthmatic patients than in controlled asthmatic 
patients. Kilic, et al.7 reported that there is a negative associa-
tion between hs-CRP and the asthma control test (ACT). How-
ever, in the present study, we could not prove a statistically sig-
nificant relationship between hs-CRP and asthma severity 
according to NHLBI guidelines.20 The discrepancies between 
the results might be due to the fact that while ACT reflects the 
present condition, NHLBI severities reflect conditions of the 
past four weeks. As CRP is an acute-phase reactant, it may have 
less relevance with past symptoms than with present conditions.
The present study has limitations, in that the findings were 
not compared with those of normal healthy controls. However, 
several studies already reported that hs-CRP levels were more 
increased in asthmatic patients than to healthy control gr-
oups.2,4,5,9,10,12-14 There was also only a small number of patients 
with positive hs-CRP (39 out of 276 patients, 14.1%). Addition-
ally, neutrophil and eosinophil counts from induced sputum 
were unavailable, and relationships between hs-CRP and air-
way neutrophilia could not be investigated.
In conclusion, the present study showed that serum hs-CRP 
has significant associations with indices of small airway ob-
struction. This was more prominent in patients with higher 
blood neutrophil counts. We, therefore, propose the possibili-
ty of hs-CRP as a marker for small airway inflammation.
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